Cargando…

Correction to “Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations”

Detalles Bibliográficos
Autores principales:	Sandoval-Pérez, Angélica, Winger, Beth Apsel, Jacobson, Matthew P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2022
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835821/ https://www.ncbi.nlm.nih.gov/pubmed/36493348 http://dx.doi.org/10.1021/acs.jctc.2c01157

Ejemplares similares

Assessing the Activation of Tyrosine Kinase KIT through Free Energy Calculations
por: Sandoval-Pérez, Angélica, et al.
Publicado: (2022)

Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
por: Apsel, Beth, et al.
Publicado: (2008)

Allosteric Communication across the Native and Mutated KIT Receptor Tyrosine Kinase
por: Laine, Elodie, et al.
Publicado: (2012)

The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
por: Disel, Umut, et al.
Publicado: (2019)

Expression of KIT Receptor Tyrosine Kinase in Endothelial Cells of Juvenile Brain Tumors
por: Puputti, Marjut, et al.
Publicado: (2009)

The Inherent Coupling of Intrinsically Disordered Regions in the Multidomain Receptor Tyrosine Kinase KIT
por: Ledoux, Julie, et al.
Publicado: (2022)

Role and significance of c-KIT receptor tyrosine kinase in cancer: A review
por: Sheikh, Emana, et al.
Publicado: (2022)

Mechanism of immune escape mediated by receptor tyrosine kinase KIT in thyroid cancer
por: Luo, Zhen, et al.
Publicado: (2023)

Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population
por: Shukla, Praveen, et al.
Publicado: (2020)

Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
por: Dubreuil, Patrice, et al.
Publicado: (2009)

Tyrosine Kinase Inhibitors Induce Down-Regulation of c-Kit by Targeting the ATP Pocket
por: D'allard, Diane, et al.
Publicado: (2013)

Mutated KIT Tyrosine Kinase as a Novel Molecular Target in Acute Myeloid Leukemia
por: Katagiri, Seiichiro, et al.
Publicado: (2022)

Cell-free expression of functional receptor tyrosine kinases
por: He, Wei, et al.
Publicado: (2015)

Does Generic Cyclic Kinase Insert Domain of Receptor Tyrosine Kinase KIT Clone Its Native Homologue?
por: Ledoux, Julie, et al.
Publicado: (2022)

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells
por: Abbaspour Babaei, Maryam, et al.
Publicado: (2016)

Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors
por: Obata, Y, et al.
Publicado: (2017)

KIT-Associated Familial GIST Syndrome: Response to Tyrosine Kinase Inhibitors and Implications for Risk Management
por: Brodey, Alexandra, et al.
Publicado: (2022)

A Guidance for Concomitant Drug Reconciliation Prior to Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults
por: Apsel Winger, Beth, et al.
Publicado: (2021)

Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1
Publicado: (1996)

Selecting Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor with Secondary KIT Activation-Loop Domain Mutations
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2013)

Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands
por: Zhao, Meng, et al.
Publicado: (2020)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Metallopeptidase inhibitor 1 (TIMP‐1) promotes receptor tyrosine kinase c‐Kit signaling in colorectal cancer
por: Nordgaard, Cathrine, et al.
Publicado: (2019)

Folding and Intrinsic Disorder of the Receptor Tyrosine Kinase KIT Insert Domain Seen by Conventional Molecular Dynamics Simulations
por: Ledoux, Julie, et al.
Publicado: (2021)

Calculation of the Free Energy and Cooperativity of Protein Folding
por: Kentsis, Alex, et al.
Publicado: (2007)

Saturation Mutagenesis by Efficient Free-Energy Calculation
por: Jandova, Zuzana, et al.
Publicado: (2017)

Dummy Atoms in Alchemical Free Energy Calculations
por: Fleck, Markus, et al.
Publicado: (2021)

Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations
por: Voice, Angus T., et al.
Publicado: (2021)

Predicting resistance of clinical Abl mutations to targeted kinase inhibitors using alchemical free-energy calculations
por: Hauser, Kevin, et al.
Publicado: (2018)

Assessing the stability of free-energy perturbation calculations by performing variations in the method
por: Manzoni, Francesco, et al.
Publicado: (2018)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2007)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2008)

Receptor tyrosine kinase C-kit promotes a destructive phenotype of FLS in osteoarthritis via intracellular EMT signaling
por: Cao, Xu, et al.
Publicado: (2023)

Role of intracellular tyrosines in activating KIT induced myeloproliferative disease
por: Ma, Peilin, et al.
Publicado: (2012)

Calculating free energies of organic molecules on insulating substrates
por: Gaberle, Julian, et al.
Publicado: (2017)

Recent Developments in Free Energy Calculations for Drug Discovery
por: King, Edward, et al.
Publicado: (2021)

c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment
por: López-Mejía, José A., et al.
Publicado: (2022)

Targeting lymphatic vessel functions through tyrosine kinases
por: Williams, Steven P, et al.
Publicado: (2010)

Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
por: Cortes, Jorge, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_lsve5lnph84udpohaj72kkul9k